Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
StockNews.AI · 3 hours
AI Summary
Zymeworks announced Phase 1 ZW191 data at ESMO Gynaecological Cancers Congress 2026, showing meaningful activity in FRα-positive platinum-resistant ovarian cancer and FRα-negative tumors. Across ovarian and endometrial cancers, cORR reached 78.6% (FRα+) and 47.4% (FRα−), with a median PFS of 7.6 months and a manageable safety profile. Part 2a dose optimization enrollment has completed, setting the stage for dose selection and potential Phase 2/3 progression.
Sentiment Rationale
Strong cORR and DCR across FRα statuses in a hard-to-treat cancer may drive short-term upside as investors anticipate progression to later-stage trials and potential value realization from ZW191’s expanded FRα franchise.
Trading Thesis
Positive Phase 1 signals for ZW191 could catalyze near-term upside for ZYME as dose optimization and next-readouts approach.
Market-Moving
- ZW191 FRα-targeted ADC shows high activity across FRα status, potentially broadening FRα therapy.
- Part 2a dose-optimization enrollment completed; results may inform dose selection.
- Safety profile largely manageable, though high TEAEs warrant watching regulatory path.
- Upcoming data presentations may serve as near-term catalysts for ZYME.
Key Facts
- ZW191 shows strong anti-tumor activity in platinum-resistant ovarian cancer and endometrial cancer.
- FRα+ PROC cORR 78.6%; FRα- 47.4% with high DCR (100%/89.5%).
- Median PFS 7.6 months; DoR not reached at data cutoff.
- Dose-optimization enrollment completed; Part 2a results expected to guide development.
Companies Mentioned
- Zymeworks Inc. (ZYME): Presenting ZW191 data; potential near-term stock driver if Readouts persist.
- ZW191 (Zymeworks asset) (N/A): FRα-targeting antibody-drug conjugate showing strong early activity across FRα expression levels.
Industry News
Industry News: Positive early-stage data for a FRα-targeted ADC; supports near-term sentiment but no regulatory approval yet.